CAP-1002 is a cell therapy commercialized by Nippon Shinyaku, with a leading Phase III program in Duchenne Muscular Dystrophy. According to Globaldata, it is involved in 11 clinical trials, of which 8 were completed, 2 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of CAP-1002’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for CAP-1002 is expected to reach an annual total of $122 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CAP-1002 Overview
Nippon Shinyaku Overview
Nippon Shinyaku develops, manufactures, and commercializes prescribed pharmaceuticals and functional foods. The company offers products for pain, inflammation, and allergies; urological diseases; hematologic malignancies; gastrointestinal disorders; cardiovascular and metabolic diseases among others. The company produces functional foods and ingredients, including preservatives, health food ingredients, and protein preparations. Its functional food products find application in meat processing, fish processing, dairy product, prepared food, confectionery and bakery, and beverage, among others. The company operates business through a network of offices and research laboratories located in Japan, China, the UK and the US. Nippon Shinyaku is headquartered in Minami-ku, Kyoto, Japan.
The company reported revenues of (Yen) JPY148,255 million for the fiscal year ended March 2024 (FY2024), an increase of 2.8% over FY2023. In FY2024, the company’s operating margin was 22.3%, compared to an operating margin of 20.8% in FY2023. In FY2024, the company recorded a net margin of 17.4%, compared to a net margin of 15.8% in FY2023.
The company reported revenues of JPY39,131 million for the first quarter ended June 2024, an increase of 10.1% over the previous quarter.
For a complete picture of CAP-1002’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
